Pine Valley Investments Ltd Liability Co Sells 3,483 Shares of AbbVie Inc. $ABBV

Pine Valley Investments Ltd Liability Co trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 4.6% in the second quarter, Holdings Channel reports. The institutional investor owned 72,077 shares of the company’s stock after selling 3,483 shares during the quarter. Pine Valley Investments Ltd Liability Co’s holdings in AbbVie were worth $18,137,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie during the 4th quarter valued at $28,000. Imprint Wealth LLC boosted its stake in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the period. Legacy Wealth Managment LLC ID grew its holdings in AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after buying an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. purchased a new position in AbbVie during the 4th quarter valued at about $31,000. Finally, Abound Financial LLC bought a new stake in shares of AbbVie during the fourth quarter valued at about $32,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

AbbVie Price Performance

Shares of ABBV opened at $265.63 on Thursday. The firm has a market cap of $469.31 billion, a P/E ratio of 75.04, a P/E/G ratio of 0.86 and a beta of 0.30. The stock has a 50 day simple moving average of $246.98 and a two-hundred day simple moving average of $226.95. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue was up 10.2% compared to the same quarter last year. During the same period last year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 14.07 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie completed a multibillion-dollar senior notes offering to help finance its acquisition of Apogee Therapeutics. The transaction provides funding for the deal and supports AbbVie’s strategy of expanding its immunology and specialty medicines portfolio as it seeks new growth opportunities. AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition AbbVie Raises $9 Billion Debt to Fund Acquisition
• Neutral Sentiment: The Apogee financing also introduces additional leverage. While debt allows AbbVie to pursue the acquisition without issuing equity, investors will assess the impact of higher interest costs and whether Apogee’s pipeline generates sufficient returns to justify the transaction. AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition
• Neutral Sentiment: AbbVie announced its 2026 Immunology Scholarship recipients, continuing a 10-year community-support program. The announcement reinforces corporate reputation but is unlikely to materially affect earnings or the stock’s near-term valuation. AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients
• Negative Sentiment: Executive Vice President Nicholas Donoghoe sold 32,710 ABBV shares for approximately $8.18 million, reducing his holdings by about 30.5%. Insider sales can reflect personal financial planning, but the sizable transaction may create a modest negative sentiment signal for investors. AbbVie Insider Transaction

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Evercore set a $235.00 price target on shares of AbbVie in a report on Friday, May 15th. BNP Paribas Exane upped their target price on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Bank of America raised their price target on shares of AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a report on Friday, July 10th. Finally, Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $275.73.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.